Public Citizen has recently petitioned the Trump administration to take action using a federal law to allow for generic competitors of GLP-1 drugs, which are commonly used to treat obesity and diabetes. The consumer advocacy group argues that the prices of these drugs are unreasonably high, making them inaccessible for many Americans.
According to Public Citizen, the spending on these drugs by federal and state governments has put a strain on budgets. The group points out that recent agreements made with the Trump administration to make these drugs more available through programs like Medicare and Medicaid are not sufficient to address the issue of limited access.
While the proposed expansion of coverage for these health care programs and a $50 per month co-pay for Medicare beneficiaries may help some individuals, others may still struggle to afford the medication. This is because certain Medicare and Medicaid plans may choose not to participate if the prices of the drugs become a budgetary concern due to increased usage.
Overall, Public Citizen is advocating for more affordable options for GLP-1 drugs to ensure that all Americans have access to necessary treatments for obesity and diabetes. By allowing generic competitors to enter the market, the hope is that prices will decrease, making these medications more accessible to those in need.
